Table 3.
Comparisons of bone metabolism parameters of patients with T2DN among three groups
| Group | OPG (μg/l) | iPTH (pg/ml) | BGP (ng/ml) | β-CTX (pg/ml) | PINP (ng/ml) | 25-OH-VD3 (ng/ml) | Pyr/Cr (pmol/μmol) | D-Pyr/Cr (pmol/μmol) |
|---|---|---|---|---|---|---|---|---|
| Mild group | ||||||||
| VD | 3.67 ± 1.00 | 66.39 ± 7.59 | 16.10 ± 3.67 | 415.71 ± 50.43 | 36.99 ± 4.96 | 33.66 ± 8.07 | 54.91 ± 14.01 | 7.73 ± 1.48 |
| PIO | 2.77 ± 0.45* | 52.85 ± 6.82* | 12.54 ± 0.92* | 322.60 ± 67.47* | 51.33 ± 6.90* | 45.20 ± 5.69* | 41.99 ± 13.64* | 6.89 ± 1.45* |
| VD + PIO | 1.62 ± 0.58*†‡§ | 43.28 ± 4.09*†‡§ | 5.48 ± 1.95*†‡§ | 256.03 ± 45.88*†‡§ | 62.59 ± 6.15*†‡§ | 50.82 ± 7.38*†‡§ | 34.18 ± 8.91*†‡§ | 5.24 ± 1.08*†‡§ |
| Moderate group | ||||||||
| VD | 4.42 ± 0.63 | 89.94 ± 14.16 | 16.92 ± 3.23 | 438.92 ± 63.58 | 27.06 ± 5.27 | 17.88 ± 4.84 | 66.12 ± 11.75 | 8.49 ± 1.64 |
| PIO | 3.59 ± 0.78* | 66.45 ± 5.99* | 14.33 ± 3.66* | 345.50 ± 31.16* | 40.62 ± 5.26* | 27.01 ± 5.84* | 58.02 ± 7.99* | 7.40 ± 0.87* |
| VD + PIO | 2.28 ± 1.05*†‡ | 50.91 ± 8.80*†‡ | 8.80 ± 1.39*†‡ | 292.12 ± 41.37*†‡ | 50.98 ± 8.80*†‡ | 42.77 ± 4.20*†‡ | 47.87 ± 8.46*†‡ | 6.18 ± 1.41*†‡ |
| Severe group | ||||||||
| VD | 5.72 ± 0.46 | 190.14 ± 23.02 | 18.77 ± 2.52 | 509.57 ± 62.30 | 12.43 ± 2.95 | 11.12 ± 3.34 | 74.74 ± 10.02 | 10.58 ± 1.05 |
| PIO | 4.32 ± 0.29* | 116.28 ± 9.08* | 16.14 ± 2.86* | 388.53 ± 57.39* | 26.14 ± 5.79* | 20.33 ± 5.93* | 67.42 ± 8.97* | 8.85 ± 1.35* |
| VD + PIO | 2.92 ± 0.56*† | 75.49 ± 4.92*† | 12.37 ± 1.31*† | 341.30 ± 52.88*† | 37.37 ± 13.67*† | 36.57 ± 9.33*† | 56.96 ± 8.44*† | 7.06 ± 1.36*† |
Note: *P<0.05 compared with the VD group; †P<0.05 compared with the PIO group; ‡P<0.05 compared with the severe group; §P<0.05 compared with the moderate group; VD + PIO, vitamin D plus pioglitazone hydrochloride.